# Nasus Pharma Ltd (NSRX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/nasus-pharma-ltd/ JSON: https://steadybase.io/company/nasus-pharma-ltd.json Checked Nov 21, 2026. Latest filing read: Oct 19, 2026.

## Company

- Legal name: Nasus Pharma Ltd
- Ticker: NSRX (NYSE)
- SEC CIK: 0002029039
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Tel Aviv - Yafo, L3
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Emerging growth company
- Website: nasuspharma.com
- Investor relations: https://ir.nasuspharma.com/

## Key facts

- Revenue: $1.2B for the fiscal year ended Dec 31, 2025 (20-F filed Mar 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/0001493152-26-012559-index.html
- Operating income: -$4.9M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/0001493152-26-012559-index.html
- Net income: -$5.9M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/0001493152-26-012559-index.html
- SG&A: $2.7M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/0001493152-26-012559-index.html
- Shares outstanding: 9,015,383 as of Dec 31, 2025 (20-F filed Mar 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/0001493152-26-012559-index.html
- Auditor: Brightman Almagor Zohar & Co, Tel -Aviv, Israel, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/form20-f.htm

## Business

Nasus Pharma develops powder-based intranasal therapies using Nasax® technology for rapid drug delivery, improved absorption, and emergency treatments.

Source: Company website description, https://nasuspharma.com/

## Officers and directors

- Brendan P. O'Grady, Chief Executive Officer. Source: Form 3 filed Jul 31, 2026, https://www.sec.gov/Archives/edgar/data/2029039/000149315226035646/0001493152-26-035646-index.htm
- Dan Benjamin Teleman, Chief Executive Officer. Source: Form 4 filed Jul 29, 2026, https://www.sec.gov/Archives/edgar/data/2029039/000149315226035218/0001493152-26-035218-index.htm
- Nir Sassi, Chief Financial Officer. Source: Form 3 filed Nov 19, 2026, https://www.sec.gov/Archives/edgar/data/2029039/000149315226053252/0001493152-26-053252-index.htm
- Oren Elmaliah, Interim CFO. Source: Form 3 filed Sep 23, 2026, https://www.sec.gov/Archives/edgar/data/2029039/000149315226043796/0001493152-26-043796-index.htm
- Eyal Rubin, Chief Financial Officer. LinkedIn: https://linkedin.com/in/eyalrubin. Source: Form 4 filed Sep 21, 2026, https://www.sec.gov/Archives/edgar/data/2029039/000149315226043559/0001493152-26-043559-index.htm
- Dalia Megiddo, Chief Development Officer. Source: Form 3 filed Mar 27, 2026, https://www.sec.gov/Archives/edgar/data/2029039/000149315226013386/0001493152-26-013386-index.htm

## Insider trades (Form 4)

- Jun 17, 2026: Dan Benjamin Teleman (Chief Executive Officer) bought 6,550 shares, about $20,305. Source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226029484/0001493152-26-029484-index.htm
- Apr 22, 2026: Dan Benjamin Teleman (Chief Executive Officer) bought 2,900 shares, about $10,904. Source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226018607/0001493152-26-018607-index.htm
- Mar 31, 2026: Dan Benjamin Teleman (Chief Executive Officer) bought 15,000 shares, about $30,600. Source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226014503/0001493152-26-014503-index.htm

## Latest filings

- 20f filed Mar 25, 2026: https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/form20-f.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

